ForecastedResearch announcementOpportunity FOR-TR-27-002

Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

National Institutes of Health · Department of Health and Human Services

At a glance

Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) is a forecasted federal cooperative agreement opportunity from the National Institutes of Health (Department of Health and Human Services). The agency's forecast estimates an application due date of February 17, 2026; forecast dates can change. Applicant types listed as eligible include state governments, county governments, independent school districts, public colleges & universities, federally recognized tribal governments and 6 more. Cost sharing is not required. It is funded under Assistance Listing 93.350 (National Center for Advancing Translational Sciences).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Jun 27, 2025Forecast posted
Oct 15, 2025 (est.)Full notice expected
Feb 17, 2026 (est.)Application deadline
Dec 17, 2026 (est.)Est. award datenext date

Posted: Jun 27, 2025
Est. close date: Feb 17, 2026
Est. award date: Dec 17, 2026
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: Not specified
Expected awards: Not specified
Cost sharing: Not required
Funding instrument: Cooperative Agreement
Opportunity category: Discretionary
Fiscal year: FY2027

Typical awards for this program (SAM.gov listing for ALN 93.350, not this notice): NCATS Assistance: $1 - $11,215,948, average: $1,718,935

Who can apply

State governments
County governments
Independent school districts
Public colleges & universities
Federally recognized tribal governments
Public & Indian housing authorities
Native American tribal organizations
501(c)(3) nonprofits
Private colleges & universities
For-profit organizations (not small businesses)
Small businesses

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.

The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.

Areas of interest for ExTReMe could include, but are not limited to:

direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);
designer EVs (personalized to the individual patient’s needs).

Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network

How to apply

0 of 8 done · progress saved in this browser

Read the full announcement (NOFO)Eligibility, evaluation criteria, page limits and required attachments are in the full notice on Grants.gov. Open ↗
Confirm eligibility and fitCheck your organization type above; no cost sharing is required.
Register (or renew) in SAM.gov and get a UEIFree. New registrations can take several weeks; registrations must be renewed every year. Open ↗
Set up Grants.gov accessCreate a Grants.gov account and make sure someone has the Authorized Organization Representative (AOR) role. Open ↗
Watch for the full noticeThe agency estimates posting it around October 15, 2025. Save this grant to track changes.
Prepare narrative, budget and attachmentsFollow the notice's format exactly — page limits and required forms are common reasons applications are rejected.
Ask the agency contact any questions earlyChristine Happel, Ph.D. National Center for Advancing Translational Sciences (NCATS) · christine.happel@nih.gov Open ↗
Submit before February 17, 2026Submit a few days early and keep your Grants.gov confirmation and validation emails.

Assistance Listing

What is an ALN?

93.350National Center for Advancing Translational SciencesProgram →

Reported obligations under ALN 93.350

Historical data · not a prediction

FY24

$596M

FY25

$626M

FY26

— est.

Source: SAM.gov Assistance Listing 93.350. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Christine Happel, Ph.D. National Center for Advancing Translational Sciences (NCATS)
christine.happel@nih.gov
240-472-7550

Quick answers

Is “Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)” open for applications yet?

Not yet. It is a forecast — an agency's advance notice of an expected opportunity. The agency estimates posting the full notice around October 15, 2025. Forecast details and dates can change.

Who is eligible to apply for “Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)”?

The official notice lists these applicant types as eligible: State governments, County governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Private colleges & universities, For-profit organizations (not small businesses) and Small businesses. Additional restrictions may apply; review the full notice.

How do I apply for “Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity FOR-TR-27-002), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

ForecastedResearchALN 93.350